Trial Profile
A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- 05 Oct 2022 Results(n=8) in female patients assessing efficacy and safety of apremilast as an add-on therapy in patients with recalcitrant cutaneous dermatomyositis, published in the JAMA Dermatology
- 07 Jul 2021 Status changed from recruiting to completed.
- 08 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Feb 2021.